Historical Valuation
SOPHiA GENETICS SA (SOPH) is now in the Fair zone, suggesting that its current forward PS ratio of 3.76 is considered Fairly compared with the five-year average of -4.65. The fair price of SOPHiA GENETICS SA (SOPH) is between 0.46 to 13.21 according to relative valuation methord.
Relative Value
Fair Zone
0.46-13.21
Current Price：4.96
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
SOPHiA GENETICS SA (SOPH) has a current Price-to-Book (P/B) ratio of 5.22. Compared to its 3-year average P/B ratio of 2.23 , the current P/B ratio is approximately 133.87% higher. Relative to its 5-year average P/B ratio of 2.53, the current P/B ratio is about 106.76% higher. SOPHiA GENETICS SA (SOPH) has a Forward Free Cash Flow (FCF) yield of approximately -11.69%. Compared to its 3-year average FCF yield of -20.85%, the current FCF yield is approximately -43.93% lower. Relative to its 5-year average FCF yield of -21.50% , the current FCF yield is about -45.63% lower.
P/B
Median3y
2.23
Median5y
2.53
FCF Yield
Median3y
-20.85
Median5y
-21.50
Competitors Valuation Multiple
AI Analysis for SOPH
The average P/S ratio for SOPH competitors is 1.34, providing a benchmark for relative valuation. SOPHiA GENETICS SA Corp (SOPH.O) exhibits a P/S ratio of 3.76, which is 179.63% above the industry average. Given its robust revenue growth of 22.77%, this premium appears sustainable.
Performance Decomposition
AI Analysis for SOPH
1Y
3Y
5Y
Market capitalization of SOPH increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SOPH in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SOPH currently overvalued or undervalued?
SOPHiA GENETICS SA (SOPH) is now in the Fair zone, suggesting that its current forward PS ratio of 3.76 is considered Fairly compared with the five-year average of -4.65. The fair price of SOPHiA GENETICS SA (SOPH) is between 0.46 to 13.21 according to relative valuation methord.
What is SOPHiA GENETICS SA (SOPH) fair value?
SOPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of SOPHiA GENETICS SA (SOPH) is between 0.46 to 13.21 according to relative valuation methord.
How does SOPH's valuation metrics compare to the industry average?
The average P/S ratio for SOPH's competitors is 1.34, providing a benchmark for relative valuation. SOPHiA GENETICS SA Corp (SOPH) exhibits a P/S ratio of 3.76, which is 179.63% above the industry average. Given its robust revenue growth of 22.77%, this premium appears sustainable.
What is the current P/B ratio for SOPHiA GENETICS SA (SOPH) as of Jan 09 2026?
As of Jan 09 2026, SOPHiA GENETICS SA (SOPH) has a P/B ratio of 5.22. This indicates that the market values SOPH at 5.22 times its book value.
What is the current FCF Yield for SOPHiA GENETICS SA (SOPH) as of Jan 09 2026?
As of Jan 09 2026, SOPHiA GENETICS SA (SOPH) has a FCF Yield of -11.69%. This means that for every dollar of SOPHiA GENETICS SA’s market capitalization, the company generates -11.69 cents in free cash flow.
What is the current Forward P/E ratio for SOPHiA GENETICS SA (SOPH) as of Jan 09 2026?
As of Jan 09 2026, SOPHiA GENETICS SA (SOPH) has a Forward P/E ratio of -4.79. This means the market is willing to pay $-4.79 for every dollar of SOPHiA GENETICS SA’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for SOPHiA GENETICS SA (SOPH) as of Jan 09 2026?
As of Jan 09 2026, SOPHiA GENETICS SA (SOPH) has a Forward P/S ratio of 3.76. This means the market is valuing SOPH at $3.76 for every dollar of expected revenue over the next 12 months.